Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Report
Submitted by
Amelita Artigas Fernandez
External Environment Analysis
Opportunities Weight Rank Weighted
Score
1. Strategic agreements with other pharmaceutical 0.09 3 0.27
companies and organizations to boost its research.
License agreement with: Medarex, Puma Biotechnology,
Eisai and etc.
4.Increase market competition. There are over 25 big international 0.06 3 0.18
pharmaceutical companies that exist today. Each of them has its own
share of the market.
THREATS
Threats Weight Rank Weigh
ted
Score
5. Losing of patent individually by focusing only one product. 0.08 3 0.24
Pfizer (PFE) is struggling to revive its top line growth. With the loss of patent
protection for its flagship drug, Lipitor, Pfizers revenue fell to $48.8 billion
in 2015, compared to $67 billion in 2010. Lipitor was a major contributor for
Pfizer, adding $10.7 billion in revenue to its top line in 2010. However,
following its generic availability, the drugs revenue fell to $1.9 billion in
2015.
6. Loss of patent protection of major products. 0.07 4 0.27
Loss of patent protection for its flagship drug, Lipitor, Pfizers revenue fell to
$48.8 billion in 2015.
THREATS
Threats Weight Rank Weigh
ted
Score
7. Risk of Eisai terminating long standing partnership. 0.04 3 0.12
Pfizer agrees with Eisai to provide Aricept to patients suffering from Alzheimers
disease. But, Japanese drug maker Eisai Co. claims it has the right to terminate an
Alzheimer's drug partnership with Pfizer Inc. once Pfizer closes its purchase of
Wyeth.
There are over 25 big international pharmaceutical companies that exist today.
9.Negatively publicized by sued by their customer. 2002, Pfizer Paid $49 Million 0.04 4 0.15
fine based on claims that it defrauded the Medicaid program and overcharge
consumers for Lipitor.
THREATS
Weight Rank Weighted
Threats
Score
Negatively publicized by sued by their customer. 2002, Pfizer Paid $49 Million fine based 0.04 4 0.15
on claims that it defrauded the Medicaid program and overcharge consumers for Lipitor.
Pfizer got a total score of 2.88 for its External Factor Evaluation (EFE) matrix,
an above average response to its existing opportunities and threats in the
industry. The current strategies that the company is using is satisfactory but
these will need to be improved for Pfizer to keep the top position among its
competitors.